ArticleCureus2024
Peripartum Cesarean Hysterectomy for Placenta Percreta: A Retrospective Analysis of Cases With and Without Extrauterine Disease.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective The aim of this study was to compare maternal morbidity and prenatal characteristics in placenta percreta cases with extrauterine disease and those with disease confined to the uterus. Methods A retrospective analysis of prospectively collected data was done at a large tertiary referral center in Egypt from October 2018 through February 2023. A total number of 73 cases who underwent primary cesarean hysterectomy with intrapartum confirmation of placenta previa percreta where there was evidence of at least placental invasion through uterine serosa (International Federation of Gynecology and Obstetrics (FIGO) grade 3) were included. Women without extrauterine disease (FIGO grade 3a) were compared to women with extrauterine disease where there was evidence of invasion of the bladder, parametrium, or both (FIGO grades 3b and 3c). Results Of 73 women included in the study, 46 women showed no evidence of extrauterine disease (group A), while the remaining 27 women had extrauterine disease (group B). The estimated amount of blood loss (mL) was 1,972 ± 671 in group A compared with 3,544 ± 899 in group B. There were no cases requiring massive transfusion in group A compared with eight of 27 cases (29.6%) in group B. Only two cases (4.3%) in group A had bladder injuries compared with 12 cases (44.4%) in group B. All 27 cases in group B required additional measures to control ongoing pelvic bleeding after hysterectomy compared with none of the cases in group A. The operating time (minutes) was 184 ± 30 in group A compared with 254 ± 42 in group B. Only five cases (10.9 %) in group A required postoperative intensive care unit admission, compared with 13 cases (48.1%) in group B. Conclusion Placenta accreta spectrum (PAS) with extrauterine disease represents the ultimate level of PAS surgery as it is more difficult, complex, and associated with the highest maternal morbidity. Highly specialized PAS centers are advised to categorize the disease into two different entities: PAS with extrauterine disease and PAS with disease confined to the uterus, as this may aid in improving the diagnostic accuracy of the severest PAS cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.